Skip to content

Total debt at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$31.57M-33.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$36.83M+59.4%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$305.29M-3.5%
Precigen logo
PrecigenPGEN
$98.25M+1,714%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$114.67M+3.5%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$55.99M-17.2%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $584K.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's total debt?
Palvella Therapeutics (PVLA) reported total debt of $584K in Q1 2026.
What is the long-term trend for Palvella Therapeutics's total debt?
Over 3 years (2020 to 2025), Palvella Therapeutics's total debt has grown at a -66.6% compound annual growth rate (CAGR), from $16.96M to $633K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.